Drug action on adenylate kinase activity in cerebrospinal fluid of arteriosclerotic patients.
A manifest presence of adenylate kinase activity in cerebrospinal fluid was found in patients with cerebral arteriosclerosis. This activity was significantly higher during treatment with co-dergocrine (Hydergin) compared with the two periods before and after treatment.
D000263:Adenylate Kinase / Q000134:cerebrospinal fluid*; D000375:Aging; D002463:Cell Membrane Permeability / Q000187:drug effects; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D010770:Phosphotransferases / Q000134:cerebrospinal fluid*
D004088:Dihydroergotoxine; D010770:Phosphotransferases; D000263:Adenylate Kinase